Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

Inclusion Criteria: * Understand and sign Informed Consent for this study. * Women ≥ than 18 years, (the inclusion process will be modified to recruit at least 24 premenopausal patients). * Capable, under investigator judgment, to understand the non-therapeutic nature of the study. * Diagnosed with invasive breast cancer in early, curable, stage (I or II) candidate to radical surgery as first therapeutic approach. * Her2 negative receptor status. * Any estrogen, progesterone status (the inclusion process will be modified to recruit at least 24 patients with TNBC tumors). * No previous systemic treatment for any malignancy. * No ongoing treatment with denosumab or bisphosphonates. * Tumour amenable for baseline Biopsy and punch-Biopsy after excision. * Adequate Serum calcium or albumin-adjusted serum calcium ≥ 2.0 mmol/L (8.0 mg/dL) and ≤ 2.9 mmol/L (11.5 mg/dL) * No prior history or current evidence of osteonecrosis of the jaw * No Active dental or jaw condition which requires oral surgery, including tooth extraction. Noplanned invasive dental procedures. * General Laboratory test within normality or with non-relevant deviations of normality as per investigator judgment. * Patients must have a normal organ and bone marrow function as defined local standards: Leukocytes, Absolute neutrophil count, Platelets, Total bilirubin, AST/ALT/GOT/GPT, Creatinine, Creatinine clearance, Magnesium, Phosphorus. * Subject with reproductive potential must be willing to use, in combina…